Skip to main
FLGT
FLGT logo

Fulgent Genetics (FLGT) Stock Forecast & Price Target

Fulgent Genetics (FLGT) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Fulgent Genetics Inc. demonstrates a strong financial outlook supported by its proprietary gene probes, which offer significant cost and flexibility advantages compared to competitors relying on third-party kits. The company’s dual focus on laboratory services and therapeutic development positions it well within the growing market for genetic testing and cancer treatment, providing a diversified revenue stream. Additionally, Fulgent's majority revenue generation from the United States enhances its market stability and potential for continued growth.

Bears say

Fulgent Genetics faces a challenging landscape as it seeks to scale its oncology business, with potential deterioration in service quality during nationwide rollouts posing a significant risk. Additionally, competitive pressures from other core market players, who may enhance their offerings and customer service, threaten to negatively impact Fulgent's operating results and relative market strength. The company is also susceptible to unpredictable regulatory changes and volatile industry fundamentals, which could adversely affect expected revenues and earnings.

Fulgent Genetics (FLGT) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fulgent Genetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fulgent Genetics (FLGT) Forecast

Analysts have given Fulgent Genetics (FLGT) a Buy based on their latest research and market trends.

According to 3 analysts, Fulgent Genetics (FLGT) has a Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fulgent Genetics (FLGT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.